Q1 Earnings Forecast for Nkarta Issued By HC Wainwright

Nkarta, Inc. (NASDAQ:NKTX) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Nkarta in a note issued to investors on Tuesday, November 11th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.34) for the quarter. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.41) EPS.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03.

Several other equities analysts have also recently weighed in on NKTX. Wall Street Zen upgraded Nkarta from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research report on Friday, October 31st. Stifel Nicolaus lowered their price target on Nkarta from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Nkarta in a research note on Wednesday, August 13th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Nkarta currently has an average rating of “Moderate Buy” and a consensus target price of $13.25.

Nkarta Trading Down 4.1%

Shares of NKTX stock opened at $1.88 on Wednesday. The firm’s fifty day moving average price is $2.13 and its two-hundred day moving average price is $2.01. Nkarta has a 1 year low of $1.31 and a 1 year high of $3.16. The firm has a market capitalization of $133.54 million, a P/E ratio of -1.36 and a beta of 0.86.

Hedge Funds Weigh In On Nkarta

Institutional investors have recently bought and sold shares of the business. Savant Capital LLC bought a new stake in Nkarta in the second quarter valued at approximately $36,000. SG Americas Securities LLC boosted its stake in shares of Nkarta by 35.0% during the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock worth $49,000 after acquiring an additional 6,141 shares during the period. CWM LLC increased its holdings in shares of Nkarta by 3,437.3% during the 1st quarter. CWM LLC now owns 28,157 shares of the company’s stock worth $52,000 after acquiring an additional 27,361 shares during the last quarter. Cerity Partners LLC bought a new stake in Nkarta in the 1st quarter valued at $55,000. Finally, Bailard Inc. acquired a new stake in Nkarta during the 3rd quarter valued at $61,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.